

Xiaohua Ye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3496841/publications.pdf>

Version: 2024-02-01

34
papers

1,086
citations

430754

18
h-index

434063

31
g-index

36
all docs

36
docs citations

36
times ranked

1534
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent progress in development of monoclonal antibodies against human cytomegalovirus. <i>Current Opinion in Virology</i> , 2022, 52, 166-173.	2.6	8
2	Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies. <i>Science Advances</i> , 2022, 8, eabm2546.	4.7	8
3	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. <i>Nature Communications</i> , 2021, 12, 469.	5.8	148
4	Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	10
5	Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 718-723.	13.7	128
6	A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial. <i>Npj Vaccines</i> , 2021, 6, 79.	2.9	19
7	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step. <i>PLoS Pathogens</i> , 2020, 16, e1008736.	2.1	17
8	Virome assembly and annotation in brain tissue based on next-generation sequencing. <i>Cancer Medicine</i> , 2020, 9, 6776-6790.	1.3	8
9	Antibody therapies for the treatment of COVID-19. <i>Antibody Therapeutics</i> , 2020, 3, 101-108.	1.2	10
10	Title is missing!. , 2020, 16, e1008736.		0
11	Title is missing!. , 2020, 16, e1008736.		0
12	Title is missing!. , 2020, 16, e1008736.		0
13	Title is missing!. , 2020, 16, e1008736.		0
14	Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection. <i>PLoS Pathogens</i> , 2019, 15, e1007914.	2.1	13
15	Coxsackievirus A10 atomic structure facilitating the discovery of a broad-spectrum inhibitor against human enteroviruses. <i>Cell Discovery</i> , 2019, 5, 4.	3.1	26
16	Recombinant virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope induces protective immunity in mice. <i>Antiviral Research</i> , 2019, 164, 139-146.	1.9	11
17	A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection. <i>Journal of Virology</i> , 2019, 93, .	1.5	32
18	Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	15

#	ARTICLE	IF	CITATIONS
19	Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid. <i>Journal of Virology</i> , 2018, 92, .	1.5	15
20	A 3.0-Angstrom Resolution Cryo-Electron Microscopy Structure and Antigenic Sites of Coxsackievirus A6-Like Particles. <i>Journal of Virology</i> , 2018, 92, .	1.5	14
21	A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	3.0	39
22	Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids. <i>Journal of Virology</i> , 2017, 91, .	1.5	34
23	Coxsackievirus A16 utilizes cell surface heparan sulfate glycosaminoglycans as its attachment receptor. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	3.0	20
24	Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody. <i>PLoS Pathogens</i> , 2016, 12, e1005454.	2.1	43
25	Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. <i>Vaccine</i> , 2016, 34, 5005-5012.	1.7	25
26	A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles. <i>Scientific Reports</i> , 2016, 6, 25741.	1.6	33
27	Transcutaneous immunization via rapidly dissolvable microneedles protects against hand-foot-and-mouth disease caused by enterovirus 71. <i>Journal of Controlled Release</i> , 2016, 243, 291-302.	4.8	41
28	Coxsackievirus A16-like particles produced in <i>Pichia pastoris</i> elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice. <i>Antiviral Research</i> , 2016, 129, 47-51.	1.9	28
29	High-yield production of recombinant virus-like particles of enterovirus 71 in <i>Pichia pastoris</i> and their protective efficacy against oral viral challenge in mice. <i>Vaccine</i> , 2015, 33, 2335-2341.	1.7	55
30	Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry. <i>Journal of Virology</i> , 2015, 89, 12084-12095.	1.5	49
31	A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. <i>Vaccine</i> , 2015, 33, 5779-5785.	1.7	26
32	Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms. <i>Journal of Virology</i> , 2014, 88, 72-81.	1.5	65
33	A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. <i>Vaccine</i> , 2014, 32, 4296-4303.	1.7	64
34	Neutralizing Antibodies Induced by Recombinant Virus-Like Particles of Enterovirus 71 Genotype C4 Inhibit Infection at Pre- and Post-attachment Steps. <i>PLoS ONE</i> , 2013, 8, e57601.	1.1	65